DnB Asset Management AS Trims Holdings in DaVita Inc. (NYSE:DVA)

DnB Asset Management AS reduced its position in DaVita Inc. (NYSE:DVA) by 4.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 9,070 shares of the company’s stock after selling 390 shares during the period. DnB Asset Management AS’s holdings in DaVita were worth $1,356,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Amundi increased its stake in DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after buying an additional 240,126 shares in the last quarter. FMR LLC grew its position in shares of DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in DaVita by 256.8% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock valued at $24,301,000 after purchasing an additional 116,758 shares during the period. JPMorgan Chase & Co. lifted its holdings in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Finally, Strategic Financial Concepts LLC bought a new position in DaVita in the 4th quarter worth approximately $9,371,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DVA has been the topic of several research analyst reports. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com cut DaVita from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Barclays increased their price target on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $166.33.

DaVita Trading Down 0.7 %

DVA opened at $151.82 on Wednesday. The stock has a 50-day moving average of $156.77 and a 200 day moving average of $157.44. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60. The firm has a market cap of $12.15 billion, a P/E ratio of 14.14, a P/E/G ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.